Argenx stock holds above $1,000 after a $7.32 EPS beat

Argenx stock held above $1,000 after a quarterly EPS of $7.32 and revenue of $1.54 billion. Analysts still see a $1,158.61 average target, while market value sits near $64.16 billion.

Argenx SE (NL0010832176) stock held above $1,000 after the latest completed Nasdaq session on August 28, 2026, when it closed at $1,023.21. The move sits alongside quarterly EPS of $7.32 and revenue of $1.54 billion, both above consensus, giving the shares a concrete fundamental backdrop.

Quarterly beat

The latest reported quarter showed EPS of $7.32 versus $5.86 expected, while revenue came in at $1.54 billion against $1.45 billion expected. That is a $1.46 EPS beat and a $90 million revenue beat, two figures that help explain why sentiment remains firm.

Market data in the same session put market capitalization at $64.157 billion and the stock at $1,031.66, with a 0.83% gain shown in the quote snapshot. A second market view put the Nasdaq close at $1,023.21 on August 28, 2026, which leaves the shares trading close to their recent high band.

Analyst backdrop

Analysts currently show a $1,158.61 average price target, and the same dataset notes a recent target lift to $1,250. The spread between the August 28 close of $1,023.21 and that average target is $135.40, a useful gap for investors tracking valuation against expectations.

Net margin reached 32.19% and return on equity stood at 43.59% in the latest quarter, both unusually strong for a biotech company at this scale. Those figures matter because they show the revenue beat was not only top-line driven but also flowed through to profitability.

Therapy focus

The company's lead treatment, Vyvgart, remains the clearest commercial reference point for the business. Its performance matters because the quarter's $1.54 billion revenue base needs durable product demand to keep supporting EPS strength.

For investors, the August 28 close of $1,023.21 and the $64.157 billion market cap frame the stock's current valuation lens. The shares remain sensitive to how long the $7.32 quarterly EPS can hold against future consensus and pricing assumptions.

More on Argenx stock

Argenx stock is trading with a high absolute share price, a strong quarterly beat, and analyst targets that still sit above the latest Nasdaq close. That combination keeps the debate centered on whether the current profit run-rate can persist into the next reported period.

Fact box

Company: Argenx SE

ISIN: NL0010832176

Ticker: ARGX

Exchange: Nasdaq

Price (as of August 28, 2026, 4:00 p.m. ET): $1,023.21 USD

Market cap: $64.157 billion

Sector / Industry: Biotechnology / Pharmaceuticals

Index membership: Nasdaq-100

Investor note

Argenx stock combines a $1,023.21 close with a $64.157 billion market cap and a quarterly EPS of $7.32. The latest revenue print of $1.54 billion versus $1.45 billion expected keeps the fundamental comparison clear.